Misplaced Pages

Ethambutol/isoniazid/pyrazinamide/rifampicin

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Combination medication used for tuberculosis Pharmaceutical compound
Ethambutol/isoniazid/pyrazinamide/rifampicin
Combination of
EthambutolAnti-tuberculosis medication
IsoniazidAnti-tuberculosis medication
PyrazinamideAnti-tuberculosis medication
RifampicinAnti-tuberculosis medication
Clinical data
Trade namesVoractiv, Rimstar, others
Routes of
administration
By mouth
ATC code
Identifiers
CAS Number
ChemSpider
  • none

Ethambutol/isoniazid/pyrazinamide/rifampicin, also known as ethambutol/isoniazid/pyrazinamide/rifampin, is a medication used for tuberculosis. It is a fixed dose combination of ethambutol, isoniazid, pyrazinamide, and rifampicin. It is used either alone or with other antituberculosis medication. It is taken by mouth.

Side effects are those of the underlying medications. Pyridoxine may be used to decrease the risk of numbness. It is not recommended in people with liver problems or severe kidney problems. Use may not be suitable in children. It is unclear if use during pregnancy is safe.

It is on the World Health Organization's List of Essential Medicines. It is sold under the brand names Voractiv and Rimstar in the UK.

References

  1. ^ World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 142. hdl:10665/44053. ISBN 9789241547659.
  2. British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. p. 403. ISBN 9780857111562.
  3. ^ "Rimstar Film-coated Tablet / Voractiv Film-coated Tablet - Summary of Product Characteristics (SPC) - (eMC)". www.medicines.org.uk. February 2016. Archived from the original on 20 December 2016. Retrieved 18 December 2016.
  4. World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

External links

Antimycobacterials, including tuberculosis treatment and leprostatic agents (J04)
Nucleic acid inhibitor
Rifamycins/
RNA polymerase inhibitor
Antifolates/DSI
ASA
Topoisomerase inhibitors/
quinolones
Protein synthesis inhibitor
Aminoglycosides
Oxazolidone
Polypeptide antibiotics
Cell envelope antibiotic
Peptidoglycan layer
Arabinogalactan layer
Mycolic acid layer
Other/unknown
Combinations
Portal: Categories: